T3	Concept 410 421	Gemcitabine
T4	Concept 682 690	SARS-CoV
T5	Concept 526 534	SARS-CoV
T6	Concept 152 161	2019-nCoV
T7	Concept 219 227	SARS-CoV
T8	Concept 201 205	S-29
T9	Concept 206 213	protein
R1	is-a Arg1:T8 Arg2:T9	
T10	Concept 267 276	S-protein
T11	Concept 189 197	sequence
T12	Action 228 234	shares
T13	Concept 245 248	70%
T14	Concept 249 257	identity
R7	in-context Arg1:T14 Arg2:T10	
T15	Concept 282 289	2019-30
R8	in-context Arg1:T10 Arg2:T15	
T16	Concept 338 355	human populations
T18	Action 356 362	showed
T19	Concept 363 374	disparities
R9	subject Arg1:T18 Arg2:T16	
R10	target Arg1:T18 Arg2:T19	
T20	Concept 378 392	susceptibility
R11	in-context Arg1:T19 Arg2:T20	
T22	Concept 483 490	cancers
T23	Concept 62 74	RBD-targeted
T24	Concept 75 83	SARS-CoV
T25	Concept 95 105	antibodies
T26	Concept 84 94	monoclonal
R16	has-property Arg1:T25 Arg2:T26	
R17	has-property Arg1:T25 Arg2:T23	
R18	in-context Arg1:T25 Arg2:T24	
T27	Action 141 151	neutralize
T28	Action 132 136	bind
R19	target Arg1:T27 Arg2:T6	
R20	target Arg1:T28 Arg2:T6	
R21	subject Arg1:T27 Arg2:T25	
R22	subject Arg1:T28 Arg2:T25	
A2	Negated T28
A3	Negated T27
R2	in-context Arg1:T11 Arg2:T8	
R3	in-context Arg1:T11 Arg2:T7	
R4	subject Arg1:T12 Arg2:T11	
T29	Concept 235 239	more
R5	in-context Arg1:T29 Arg2:T13	
R23	target Arg1:T12 Arg2:T29	
R6	in-context Arg1:T13 Arg2:T14	
T1	Concept 311 319	SARS-Cov
T2	Concept 324 332	MERS-Cov
R12	in-context Arg1:T20 Arg2:T2	
R13	in-context Arg1:T20 Arg2:T1	
T17	Action 457 465	treating
T21	Concept 474 479	types
T30	Concept 466 473	certain
R14	subject Arg1:T17 Arg2:T3	
R15	has-property Arg1:T21 Arg2:T30	
R24	target Arg1:T17 Arg2:T21	
R25	in-context Arg1:T21 Arg2:T22	
T31	Action 516 525	targeting
R26	subject Arg1:T31 Arg2:T3	
R27	target Arg1:T31 Arg2:T5	
